Tato stránka byla automaticky přeložena a přesnost překladu není zaručena. Podívejte se prosím na anglická verze pro zdrojový text.

Účinnost a mechanismy léčby fantomové bolesti nohou virtuální realitou

8. září 2026 aktualizováno: Laurel Buxbaum, Albert Einstein Healthcare Network

Účinnost a mechanismy léčby fantomové bolesti nohou virtuální realitou: osobní léčba

After amputation of an arm or leg, up to 90% of subjects experience a "phantom limb", a phenomenon characterized by persistent feelings of the missing limb. Many subjects with a phantom limb experience intense pain in the missing extremity that is often poorly responsive to medications or other interventions. The proposed work will contrast the efficacy of two virtual reality treatments for phantom limb pain: a 'Distractor' and an Active VR treatment. In the Distractor treatment, participants are engaged in a visually immersive virtual reality experience that does not require leg movements (REAL i-Series® immersive VR experience). In the Active VR treatment, subjects play a series of VR games using the virtual rendering of both legs.

Přehled studie

Postavení

Dokončeno

Detailní popis

Almost 2 million people in the US have had an amputation and up to 90% of people with limb amputation experience the persistent sensation of the missing extremity, a phenomenon known as a "phantom limb" (Weeks et al., 2010). Additionally, a significant proportion of individuals with a phantom limb - up to 85% in some studies - experience persistent and debilitating pain in the missing limb, a condition known as phantom limb pain (hereafter PLP). Although existing therapies provide pain relief in some cases, there is widespread agreement that current approaches fall short of bringing relief to most individuals with PLP (Weeks et al., 2010).

The investigators recently completed a proof-of-concept study (Ambron et al., 2021) in which eight subjects with below knee amputations (BKA) underwent two virtual reality (VR) treatments for PLP. In an Active VR treatment, subjects played a variety of active games requiring leg movements while receiving high-quality visual feedback of the missing lower leg. Feedback about leg position was provided via an electromagnetic system using leg sensors (trackSTAR, Ascension Technologies Inc), and the program generated an image of the missing lower leg, visible as a first-person avatar. This treatment was contrasted with a "Distractor" treatment, in which participants were engaged in a visually immersive virtual reality experience that did not require leg movements (Cool!TM). Both treatments were associated with significant reductions in pain intensity, but the Active VR treatment was also associated with reductions in pain interference, depression, and anxiety.

The specific aims of the current study are (i) to replicate our prior observations of efficacy of VR treatment in a larger sample of individuals with BKA; (ii) to test VR therapy in patients with above knee amputations; (iii) to compare the efficacy of Active VR treatment to Distractor VR treatment for PLP on measures of pain as well as psychological health and quality of life.

Typ studie

Intervenční

Zápis (Aktuální)

46

Fáze

  • Nelze použít

Kontakty a umístění

Tato část poskytuje kontaktní údaje pro ty, kteří studii provádějí, a informace o tom, kde se tato studie provádí.

Studijní místa

    • Pennsylvania
      • Elkins Park, Pennsylvania, Spojené státy, 19027
        • Moss Rehabilitation Research Institute
      • Philadelphia, Pennsylvania, Spojené státy, 19104
        • University of Pennsylvania
    • Washington
      • Seattle, Washington, Spojené státy, 98104
        • University of Washington-Harborview Medical Center

Kritéria účasti

Výzkumníci hledají lidi, kteří odpovídají určitému popisu, kterému se říká kritéria způsobilosti. Některé příklady těchto kritérií jsou celkový zdravotní stav osoby nebo předchozí léčba.

Kritéria způsobilosti

Věk způsobilý ke studiu

18 let až 100 let (Dospělý, Starší dospělý)

Přijímá zdravé dobrovolníky

Ne

Pohlaví způsobilá ke studiu

Všechno

Popis

Inclusion Criteria:

  1. Age 18 - 100 years
  2. Capacity to provide Informed Consent
  3. Unilateral above or below knee amputation more than 3 months prior to enrollment
  4. Absence of cognitive impairment, operationally defined as a Montreal Cognitive Assessment score of 18 or greater
  5. Pain averaged over the preceding 1 month in the phantom limb rated as greater than 4 on a scale of 0-10.

Exclusion Criteria:

  1. History of significant medical or neurological disorder such as stroke or moderate to severe traumatic brain injury (operationally defined as loss of consciousness for more than 30 minutes)
  2. History of significant or poorly controlled psychiatric disorders
  3. Current significant depression or anxiety as judged by the Hospital Anxiety and Depression Scale (HADS) (Zigmond & Snaith, 1983).
  4. Current abuse of alcohol or drugs, prescription or otherwise
  5. Nursing a child, pregnant, or intent to become pregnant during the study

Studijní plán

Tato část poskytuje podrobnosti o studijním plánu, včetně toho, jak je studie navržena a co studie měří.

Jak je studie koncipována?

Detaily designu

  • Primární účel: Léčba
  • Přidělení: Randomizované
  • Intervenční model: Paralelní přiřazení
  • Maskování: Žádné (otevřený štítek)

Zbraně a zásahy

Skupina účastníků / Arm
Intervence / Léčba
Experimentální: Active VR treatment

Subjects assigned to the Active VR treatment began by selecting an avatar, with features such as gender and skin color that could be chosen according to preference. During treatment, they participated in a variety of games and activities developed and used by our teams including Kick, Dog Food, Quest for Fire, Chess, Checkers, Sudoku, and surfing the internet. Subjects had substantial flexibility to select games according to their interests but were required to spend at least 30 minutes in each session in games that required forceful, large-amplitude movements of the amputated lower limb (e.g., Quest for Fire, Kick).

8 twice-weekly interventions of virtual reality treatment focused on reducing phantom limb pain.

Experimentální: Distractor VR treatment

Subjects assigned to the Distractor VR treatment participated in the REAL i-Series immersive VR experience (REAL system), which had been demonstrated to reduce pain in several studies but lacked the hypothesized "active ingredients" of our Active VR treatment (visual and auditory feedback of movement of an extrapolated amputated limb). Subjects navigated through pleasant and relaxing VR environments; they did not see any rendering of their body and made no movements with their legs.

8 twice-weekly interventions of virtual reality treatment focused on reducing phantom limb pain.

Co je měření studie?

Primární výstupní opatření

Měření výsledku
Popis opatření
Časové okno
Changes in Pain Intensity
Časové okno: Baseline versus immediately post-intervention at 4 weeks.

Visual Analogue Scale (VAS) of McGill Short Form Questionnaire (Melzack, 1987); 0 minimum score - 10 maximum score; higher scores indicate higher level of pain (worse outcome)

Baseline versus immediately post-intervention at 4 weeks.
Changes in Pain Quality
Časové okno: Baseline versus immediately post-intervention at 4 weeks.

McGill Short Form Questionnaire (Melzack, 1987): a series of 4-point scales (0 none - 3 severe) assessing the intensity of 15 qualitative characteristics of pain (e.g., throbbing, shooting, cramping, etc.), where higher scores are worse (more severe). For every participant we computed the total pain score (maximum 45 points indicating severe pain). Then, we computed the difference in the total scores between time points (e.g. post treatment vs baseline). Therefore, negative scores indicate improvement in pain qualitative characteristics.

Baseline versus immediately post-intervention at 4 weeks.

Sekundární výstupní opatření

Měření výsledku
Popis opatření
Časové okno
Changes in Average Pain
Časové okno: 1st treatment versus 8th treatment (4 weeks)

Difference between 8th and 1st treatment session on scaled score measuring "average pain intensity since the previous intervention" on an 11-point numerical rating pain scale; (Scale = 0 - minimum score/no pain to 10 maximum score/pain as bad as participants can imagine); higher scores indicate higher level of pain (worse outcome).

1st treatment versus 8th treatment (4 weeks)

Další výstupní opatření

Měření výsledku
Popis opatření
Časové okno
Changes in Daily Activities
Časové okno: Baseline versus immediately post-intervention at 4 weeks.

The Frenchay Activities Index (FAI) (Holbrook et al., 1983):1983): a scale measuring the physical function and daily activity associated with quality of life in people with amputation. Scale = 0 minimum score to 45 maximum score; higher scores indicate more daily activities (better outcome). We report the average difference between post-intervention (after 4 weeks) and pre-intervention.

Baseline versus immediately post-intervention at 4 weeks.
Changes in Quality of Life
Časové okno: Baseline versus immediately post-intervention at 4 weeks.

The 12-Item Short Form Health Survey (SF-12) (Ware et al., 1996): a measure of quality of life and functional capacity that has been validated in patients with amputation and phantom limb pain. Scale = 0 minimum score to 100 maximum score. Higher scores indicate poorer physical and mental health (worse outcome).

Baseline versus immediately post-intervention at 4 weeks.
Changes in Pain Interference
Časové okno: Baseline versus immediately post-intervention at 4 weeks

The Pain Interference Scale from the Brief Pain Inventory (BPI) (Cleeland & Ryan, 1994): A scale measuring the degree to which pain interferes with daily activities using a 0-10 numeric rating. Scale = 0 minimum score to 10 maximum score. Higher scores indicate greater pain interference (worse outcome). We report the average difference between post-intervention (after 4 weeks) and pre-intervention.

Baseline versus immediately post-intervention at 4 weeks
Changes in Depression and Anxiety
Časové okno: Baseline versus immediately post-intervention at 4 weeks.

The Hospital Anxiety and Depression Scale (HADS) (Zigmond & Snaith, 1983): This is a 14- item measure with subscales assessing depressive and anxiety symptoms. For each subscale. range = 0 minimum score to 42 maximum score. Higher scores indicate more depression and/or anxiety (worse outcome). We report average differences on the anxiety scale and the depression scales between post-intervention (after 4 weeks) and pre-intervention.

Baseline versus immediately post-intervention at 4 weeks.
Changes in Pain Catastrophizing
Časové okno: Baseline versus immediately post-intervention at 4 weeks.

The 13-item Pain Catastrophizing Scale (Sullivan et al., 1995): this scale investigates pain catastrophizing, which has been associated with pain severity and disability after amputation. Score range = 0-52; Higher scores indicate higher tendency to catastrophize (worse outcome). We report the average difference between post-intervention (after 4 weeks) and pre-intervention.

Baseline versus immediately post-intervention at 4 weeks.
Changes in Insomnia
Časové okno: Baseline versus immediately post-intervention at 4 weeks.

Insomnia Severity Index (Bastien et al., 2001): a 7-point scale that measures insomnia, a symptom associated with phantom limb pain. Score range = 0-28; higher scores indicate more insomnia (worse outcome). We report the average difference between post-intervention (after 4 weeks) and pre-intervention.

Baseline versus immediately post-intervention at 4 weeks.
Acceptance of VR System
Časové okno: Baseline

Technology Acceptance Scale (Morris et al., 1997): this is a 7-point scale that measures level of acceptance of the VR system. 0 minimum score - 133 maximum score; higher scores indicate low level of acceptance (worse score).

Baseline
Usability of the Treatment
Časové okno: immediately after the last intervention (session 8 of the intervention), an average of 4 weeks

System Usability Scale (SUS) (Brooke, 1996); Scale measuring the usability of the each game; minimum score 10 - maximum score 50. Higher scores indicate less usability (worse outcome). For the distractor treatment, participants rated the overall experience; for the active treatment, the average of the two games was computed for each participants.

immediately after the last intervention (session 8 of the intervention), an average of 4 weeks
Cybersickness
Časové okno: 1st (week 1) and 8th (week 4) treatment sessions

Simulator Sickness Questionnaire - SSQ (Kennedy et al., 1993): 4 points (0 - none; 3 - severe) scale assessing the severity of 16 cybersickness motion sickness symptoms, like nausea or dizziness. We computed the average score across items.

1st (week 1) and 8th (week 4) treatment sessions
Presence in VR
Časové okno: 1st (week 1) and 8th (week 4) treatment sessions.

Brief Slater-Usoh-Steed Presence Questionnaire (Usoh et al., 2000; Slater et al., 1998; 1994). 0 minimum score - 42 maximum score. Higher scores indicate more presence in the VR (better outcome

1st (week 1) and 8th (week 4) treatment sessions.
Changes in Pain at Its Worst
Časové okno: Baseline versus immediately post-intervention at 4 weeks

The Modified Limb Deficiency and Phantom Limb Questionnaire (Goller et al., 2013): a questionnaire and visual analog scale assessing prosthesis usage, phantom limb experiences, and pain severity. The outcome measure used was the score on the visual analogue scale assessing pain severity at its worst (Scale = 0 no pain to 10 unbearable pain). We report the average score difference between post-intervention (after 4 weeks) and pre-intervention.

Baseline versus immediately post-intervention at 4 weeks
Treatment Satisfaction
Časové okno: 1 week after the end of the intervention, an average of 5 weeks

Visual analogue scale that evaluates treatment satisfaction (Robinson et al., 2004; Smith et al., 2005); 0 minimum score - 10 maximum score; Higher scores indicate more treatment satisfaction (better outcome)

1 week after the end of the intervention, an average of 5 weeks

Spolupracovníci a vyšetřovatelé

Zde najdete lidi a organizace zapojené do této studie.

Vyšetřovatelé

  • Vrchní vyšetřovatel: Laurel Buxbaum, PsyD, Albert Einstein Healthcare Netork

Publikace a užitečné odkazy

Osoba odpovědná za zadávání informací o studiu tyto publikace poskytuje dobrovolně. Mohou se týkat čehokoli, co souvisí se studiem.

Obecné publikace

Termíny studijních záznamů

Tato data sledují průběh záznamů studie a předkládání souhrnných výsledků na ClinicalTrials.gov. Záznamy ze studií a hlášené výsledky jsou před zveřejněním na veřejné webové stránce přezkoumány Národní lékařskou knihovnou (NLM), aby se ujistily, že splňují specifické standardy kontroly kvality.

Hlavní termíny studia

Začátek studia (Aktuální)

10. května 2022

Primární dokončení (Aktuální)

16. března 2025

Dokončení studie (Aktuální)

6. dubna 2025

Termíny zápisu do studia

První předloženo

9. února 2022

První předloženo, které splnilo kritéria kontroly kvality

24. března 2022

První zveřejněno (Aktuální)

25. března 2022

Aktualizace studijních záznamů

Poslední zveřejněná aktualizace (Aktuální)

30. září 2026

Odeslaná poslední aktualizace, která splnila kritéria kontroly kvality

8. září 2026

Naposledy ověřeno

1. září 2026

Více informací

Termíny související s touto studií

Plán pro data jednotlivých účastníků (IPD)

Plánujete sdílet data jednotlivých účastníků (IPD)?

ANO

Popis plánu IPD

After de-identification, individual participant data to be shared included descriptors of clinical status (e.g., time since amputation, level of amputation), background test battery results, and outcome measures results.

Časový rámec sdílení IPD

Immediately following publication. No end date.

Kritéria přístupu pro sdílení IPD

Researchers who provide a sound rationale.

Typ podpůrných informací pro sdílení IPD

  • PROTOKOL STUDY

Informace o lécích a zařízeních, studijní dokumenty

Studuje lékový produkt regulovaný americkým FDA

Ne

Studuje produkt zařízení regulovaný americkým úřadem FDA

Ne

Tyto informace byly beze změn načteny přímo z webu clinicaltrials.gov. Máte-li jakékoli požadavky na změnu, odstranění nebo aktualizaci podrobností studie, kontaktujte prosím register@clinicaltrials.gov. Jakmile bude změna implementována na clinicaltrials.gov, bude automaticky aktualizována i na našem webu .

Předplatit